Eli Lilly's drug cuts COVID-19 recovery time in remdesivir-combo study

By Manas Mishra (Reuters) - Eli Lilly and Co said on Monday its rheumatoid arthritis drug shortened the time to recovery in hospitalized COVID-19 patients when used along with Gilead Sciences Inc's remdesivir. The drug baricitinib, branded as Olumiant, cut the median recovery time by about a day when added to remdesivir, compared to patients treated with the antiviral alone, Lilly said. Remdesivir was granted an emergency use authorization (EUA) in May after trial data showed it helped shorten hospital recovery time by 31%

Reuters September 15, 2020 00:07:15 IST
Eli Lilly's drug cuts COVID-19 recovery time in remdesivir-combo study

COVID-19 recovery time in remdesivir-combo study" src="https://images.firstpost.com/wp-content/uploads/reuters/09-2020/15/2020-09-14T165156Z_1_LYNXMPEG8D1PX_RTROPTP_2_LILLY-BUSINESS.jpg" alt="Eli Lillys drug cuts COVID19 recovery time in remdesivircombo study" width="300" height="225" />

By Manas Mishra

(Reuters) - Eli Lilly and Co said on Monday its rheumatoid arthritis drug shortened the time to recovery in hospitalized COVID-19 patients when used along with Gilead Sciences Inc's remdesivir.

The drug baricitinib, branded as Olumiant, cut the median recovery time by about a day when added to remdesivir, compared to patients treated with the antiviral alone, Lilly said.

Remdesivir was granted an emergency use authorization (EUA) in May after trial data showed it helped shorten hospital recovery time by 31%.

Lilly said it plans to discuss the potential for an EAU for baricitinib with the U.S. Food and Drug Administration, based on the results from the trial, which tested more than 1,000 patients.

"As an already approved and available drug, we believe baricitinib could serve as an important additional treatment option as the medical community continues to learn how to best manage patients hospitalized with COVID-19 ," said Mizuho analyst Vamil Divan.

The drug, licensed by Lilly from Incyte Corp, could help suppress a potentially lethal immune response to COVID-19 called "cytokine storm".

U.S. hospitals have turned down about a third of their allocated supplies of remdesivir since July as need for the costly drug wanes, the Department of Health and Human Services (HHS) confirmed on Friday.

Remdesivir costs $3,120 for a six-vial course.

Eli Lilly in June also began a late-stage study to test baricitinib as a monotherapy in hospitalized patients across the United States, Europe, Asia and Latin America.

(Reporting by Manas Mishra in Bengaluru; Editing by Saumyadeb Chakrabarty, Shinjini Ganguli and Sriraj Kalluvila)

This story has not been edited by Firstpost staff and is generated by auto-feed.

Updated Date:

TAGS:

also read

Greek police clash with protesters in rally against mandatory vaccinations
World

Greek police clash with protesters in rally against mandatory vaccinations

ATHENS (Reuters) - Greek police used teargas and water cannon to disperse people who had gathered in central Athens on Saturday to protest against mandatory COVID-19 vaccinations. More than 4,000 people rallied outside the Greek parliament for a third time this month to oppose mandatory inoculations for some workers, such as healthcare and nursing staff.

Two Turkish soldiers killed in attack in northern Syria
World

Two Turkish soldiers killed in attack in northern Syria

ISTANBUL (Reuters) - Two Turkish soldiers were killed and two were wounded in an attack on their armoured vehicle in northern Syria, and Turkish forces immediately launched retaliatory fire, Turkey's defence ministry said on Saturday. "Our punitive fire against terrorist positions is continuing," the statement on Twitter on said. It did not specify where the attack occurred, but media reports said it was in the al-Bab area.

Brazilians take to streets again to demand Bolsonaro's impeachment
World

Brazilians take to streets again to demand Bolsonaro's impeachment

By Marcelo Rochabrun SAO PAULO (Reuters) - Protesters took to the streets in several Brazilian cities on Saturday to demand the impeachment of far-right President Jair Bolsonaro, whose popularity has fallen in recent weeks amid corruption scandals against the backdrop of the pandemic. This week, news broke that Brazil's defense ministry told congressional leadership that next year's elections would not take place without amending the country's electronic voting system to include a paper trail of each vote. Bolsonaro has suggested several times without evidence that the current system is prone to fraud, allegations that Brazil's government has denied